U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H23N3O.C9H10N4O4
Molecular Weight 523.5851
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEPIFYLLINE

SMILES

CN(C)CCN(Cc1ccc(cc1)OC)c2ccccn2.Cn1c2c(c(=O)n(C)c1=O)n(CC(=O)O)cn2

InChI

InChIKey=TXBZJCTVHPHWPH-UHFFFAOYSA-N
InChI=1S/C17H23N3O.C9H10N4O4/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15;1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15/h4-11H,12-14H2,1-3H3;4H,3H2,1-2H3,(H,14,15)

HIDE SMILES / InChI

Molecular Formula C9H10N4O4
Molecular Weight 238.2005
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H23N3O
Molecular Weight 285.3847
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Acefylline is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. Acephylline piperazine is a theophylline derivative with a direct bronchodilator action. It has the advantages over theophylline in being far less toxic and producing minimal gastric irritation. It is indicated for the treatment of asthma, emphysema, acute and chronic bronchitis associated with bronchospasm.Acefylline relaxes smooth muscles, relieves bronchospasm & has a stimulant effect on respiration. It stimulates the myocardium & central nervous system, decreases peripheral resistance & venous pressure & causes diuresis. The mechanism of action is still not clear, inhibition of phosphodiesterase with a resulting increase in intracellular cyclic AMP does occur, but not apparently at concentrations normally used for clinical effect. Other proposed mechanisms of action include adenosine receptor antagonism, prostaglandin antagonism & effects on intracellular calcium. Sodium phenobarbital is a non-selective central nervous system depressant that is primarily used as sedative-hypnotic.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
27.6 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
PubMed

PubMed

TitleDatePubMed
Solid-state chemistry of ambroxol theophylline-7-acetate.
2007 May
Molecularly imprinted polymers for ochratoxin a extraction and analysis.
2010 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can be used orally: Dosage: 2 to 6 tablets daily, in several doses at regular intervals during the day. Composition: Each coated tablet contains: - Acefylline piperazine 0.250 g http://www.unipharma-sy.com/en/MedicineView/48/142/ETAPHYLLINE_.aspx
Dosage & route of administration & duration: The optimum therapeutic serum concentration is considered to range from 10 to 20 mcg/ml To avoid adverse effects the rate of infusion administration should not exceed 20 mg / min For I.M & slow I.V injection of 200 mg over at least 15 min. For IV infusion a loading dose of 4 mg/kg may be given over 20 to 30 min followed by a suggested maintenance dose of 0.5 mg /kg / hour reduced after 12 hours to 0.4 mg/kg/hour. Suggested Doses for children: 4mg/Kg by slow IV injection over at least 15 min or by infusion with a loading dose of 4 mg/kg followed by maintenance doses of: Children from 6 months to 6 years...................0.8 to 1 mg/kg/hour, reduced after the first 12 hours to 0.6 mg/kg/hour. Children over 6 years.....................................0.75 mg/kg/hour, reduced after the first 12 hours to 0.5 mg/kg/hour.
Route of Administration: Parenteral
After topical application of a gel formulation containing 3% acefylline at the surface of reconstructed human epidermis, immunoblotting analysis showed an increase in the total amount of deiminated proteins, and confocal microscopy showed an enhanced deimination in the stratum corneum. This demonstrated the activation of PADs in living cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:47:50 UTC 2021
Edited
by admin
on Sat Jun 26 02:47:50 UTC 2021
Record UNII
20HD67185N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEPIFYLLINE
Common Name English
MADE-27110
Code English
MEPYRAMINE THEOPHYLLINE ACETATE
Common Name English
MEPIPHYLLINE
WHO-DD  
Common Name English
MEPIPHYLLINE [WHO-DD]
Common Name English
MEPYRAMINE 7-THEOPHYLLINEACETATE
Common Name English
7H-PURINE-7-ACETIC ACID, 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-, COMPD. WITH N-((4-METHOXYPHENYL)METHYL)-N',N'-DIMETHYL-N-2-PYRIDINYL-1,2-ETHANEDIAMINE (1:1)
Common Name English
MEPIFILINE
Common Name English
Classification Tree Code System Code
WHO-ATC R03DA12
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
Code System Code Type Description
EVMPD
SUB21039
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
FDA UNII
20HD67185N
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
EPA CompTox
57383-74-1
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
EVMPD
SUB182736
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
CAS
57383-74-1
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
PUBCHEM
162821
Created by admin on Sat Jun 26 02:47:50 UTC 2021 , Edited by admin on Sat Jun 26 02:47:50 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY